In October 2013 NICE produced guidance (DG11) recommending the use of faecal calprotectin testing to help doctors distinguish between inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, and non-inflammatory bowel diseases, such as irritable bowel syndrome. You can read more about the NICE guidelines here.
The Health Technologies Adoption Programme (HTAP) are now seeking NHS acute trusts and primary care organisations that wish to introduce faecal calprotectin testing into their clinical pathways, in order to work with them to support implementation and become ‘adoption sites’ for the technology.
The NICE HTAP is currently developing a pack to support implementation of DG11, which will identify barriers and challenges whilst demonstrating any clinical and financial benefits.
More information is available on what is required for implementation, and describes the support HTAP will provide to organisations adopting faecal calprotectin testing.
The resource and time commitment as an adopter site will be no greater than the resource needed to implement the technology itself – NICE will provide all administrative and technical support. A small amount of funding (up to £3000) per adoption project is available.
NHS organisations expressing an interest will be asked to complete a short questionnaire, which will be used to select the adoption sites. The closing date for expressing an interest is the 30 November 2013.